OSE Immunotherapeutics Stock Other OTC
Stocks
ORPOF
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 80.16M 91.63M 73.92M 68.39M 130M 8.75B 132M 885M 347M 4.29B 344M 337M 14.88B | P/E 2026 * |
-2.62x | P/E 2027 * | -3x |
|---|---|---|---|---|---|
| Enterprise Value | 121M 138M 112M 103M 196M 13.2B 199M 1.34B 524M 6.48B 519M 508M 22.45B | EV / Sales 2026 * |
24.7x | EV / Sales 2027 * | 13.6x |
| Free-Float |
74.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OSE Immunotherapeutics
| 1 day | -15.79% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 02/10/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 20/08/2025 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 20/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 31/05/2016 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 14/06/2017 |
| Director/Board Member | - | 22/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.79% | -.--% | - | - | 91.63M | |
| +1.37% | +2.79% | +3.65% | +11.65% | 50.44B | |
| +0.72% | +1.00% | +396.18% | +624.25% | 40.63B | |
| +2.54% | +0.93% | +28.98% | -3.62% | 34.88B | |
| +0.31% | +1.74% | +18.44% | +59.76% | 33.67B | |
| -2.09% | -1.98% | +3.21% | +33.56% | 26.29B | |
| -0.63% | +0.34% | - | - | 17.11B | |
| +0.66% | -3.96% | +66.85% | +127.36% | 15.29B | |
| -23.90% | -21.43% | +50.06% | +53.83% | 10.62B | |
| +1.40% | +0.58% | +15.08% | +22.51% | 13.74B | |
| Average | -3.54% | -2.71% | +72.81% | +116.16% | 26.96B | |
| Weighted average by Cap. | -0.38% | -0.61% | +87.60% | +139.87% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.6M 4.52M 4.18M 7.94M 535M 8.07M 54.11M 21.21M 263M 21.03M 20.57M 909M | 10.53M 12.04M 9.71M 8.98M 17.05M 1.15B 17.34M 116M 45.59M 564M 45.19M 44.21M 1.95B |
| Net income | -30.59M -34.96M -28.21M -26.1M -49.53M -3.34B -50.36M -338M -132M -1.64B -131M -128M -5.68B | -21.47M -24.54M -19.8M -18.32M -34.77M -2.34B -35.35M -237M -92.93M -1.15B -92.12M -90.13M -3.98B |
| Net Debt | 40.79M 46.63M 37.62M 34.8M 66.06M 4.45B 67.16M 450M 177M 2.19B 175M 171M 7.57B | 63.08M 72.11M 58.17M 53.83M 102M 6.88B 104M 697M 273M 3.38B 271M 265M 11.71B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
